Literature DB >> 9841850

Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis.

M Koot1, R van Leeuwen, R E de Goede, I P Keet, S Danner, J K Eeftinck Schattenkerk, P Reiss, M Tersmette, J M Lange, H Schuitemaker.   

Abstract

The presence of syncytium-inducing (SI) human immunodeficiency virus type 1 (HIV-1) variants is predictive for accelerated progression to AIDS. This study showed that a 4-year survival with AIDS also occurred significantly more often for patients who lacked SI variants. However, multivariate Cox analysis excluded the predictive value of SI viruses for rapid death as being independent from low CD4+ T cell counts. Incidence of appearance of SI variants was increased in persons with CD4+ T cell counts <500/microliter but remained constant in the strata of CD4+ T cell counts <500/microliter, excluding the possibility that loss of immune control is the only prerequisite for the development of SI HIV-1 variants.

Entities:  

Mesh:

Year:  1999        PMID: 9841850     DOI: 10.1086/314539

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  37 in total

1.  2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.

Authors: 
Journal:  Infect Dis Obstet Gynecol       Date:  2002

2.  Unusual five amino acid insert within subtype C HIV-1 envelope contributes to dual-tropism (X4R5).

Authors:  Elizabeth Johnston White; Bryan McColgan; Seble Kassaye; Lynn Zijenah; David Katzenstein
Journal:  AIDS       Date:  2010-04-24       Impact factor: 4.177

3.  Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.

Authors:  Mike Westby; Marilyn Lewis; Jeannette Whitcomb; Mike Youle; Anton L Pozniak; Ian T James; Tim M Jenkins; Manos Perros; Elna van der Ryst
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  Target cell populations of human immunodeficiency virus type 1 in peripheral blood lymphocytes with different chemokine receptors at various stages of disease progression.

Authors:  P Auewarakul; K Sangsiriwut; S Suwanagool; C Wasi
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Identification of broadly recognized, T helper 1 lymphocyte epitopes in an equine lentivirus.

Authors:  Darrilyn G Fraser; J Lindsay Oaks; Wendy C Brown; Travis C McGuire
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

6.  Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.

Authors:  Evelien M Bunnik; Esther D Quakkelaar; Ad C van Nuenen; Brigitte Boeser-Nunnink; Hanneke Schuitemaker
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  Real-time PCR assay of individual human immunodeficiency virus type 1 variants in coinfected human lymphoid tissues.

Authors:  Yoshinori Ito; Jean-Charles Grivel; Leonid Margolis
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

8.  Major coexisting human immunodeficiency virus type 1 env gene subpopulations in the peripheral blood are produced by cells with similar turnover rates and show little evidence of genetic compartmentalization.

Authors:  William L Ince; Patrick R Harrington; Gretja L Schnell; Milloni Patel-Chhabra; Christina L Burch; Prema Menezes; Richard W Price; Joseph J Eron; Ronald I Swanstrom
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

9.  Evolution of human immunodeficiency virus type 1 coreceptor usage during antiretroviral Therapy: a Bayesian approach.

Authors:  Christina M R Kitchen; Sean Philpott; Harold Burger; Barbara Weiser; Kathryn Anastos; Marc A Suchard
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

10.  Maraviroc in the treatment of HIV infection.

Authors:  Neelanjana Ray
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.